Evaluation of the efficacy and safety of Adalimumab and methylprednisolone pulse therapy in treatment of Covid-19 patients with Acute respiratory distress syndrome

Evaluation of the efficacy and safety of Adalimumab and methylprednisolone pulse therapy in treatment of Covid-19 patients with ARDS

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200406046963N2

Enrollment

Registered

2021-07-31

Start date

2021-06-18

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 Disease. COVID-19

Interventions

Intervention 1: Intervention group: Patients hospitalized with COVID-19 disease who in addition to their standard treatment ( Hydroxychloroquine 400mg daily) will be received 1000mg/day Methylpredniso

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patient with moderate to severe Covid-19 admitted to ICU PaO2/FiO2 Less than 300 LDH more than 450 Progression of disease severity and not responding to standard treatment prediction of intubation for next 24 hours

Exclusion criteria

Exclusion criteria: Uncontrolled diabetes mellitus Active GI bleeding history of corticosteroid hypersensitivity sever electrolyte imbalances Procalcitonin more than 0.5 active bacterial, viral ( HIV, Hepatitis) and fungal infection

Design outcomes

Primary

Measure	Time frame
Mortality rate. Timepoint: from including to study to 60 days. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEbrahim Hazrati

Artesh University of Medical Sciences

dr.hazrart.e@gmail.com+98 21 8609 6350

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 13, 2026